Synsorb Biotech, Inc.

The Governors of the University of Alberta

Alberta Research Council Incorporated

Connaught Laboratories Limited

Other

Mcgill University

Pence, Inc.

Sybsorb Biotech, Inc.

Glen D Armstrong

Louis D Heerze

Randy J Read

Michel Henri Klein

Sheena M Loosmore

Raymond P Oomen

Richard H Smith

Stephen A Cockle

Bart Hazes

Penelope E Stein

Bradley G Thompson

David R Bundle

Robert M Ratcliffe

Pavel Kitov

David J Rafter

Rosa Vanmaele

Francois Auclair

Hermy Lior

Hong Ling

George A Wells

Andrew M MacKenzie

Paul R Goodyer

Terrance P Klassen

Elaine Orrbine

Peter C Rowe

Rosa P Vanmaele

Peter N McLaine

Robert S Hodges

Randall Thomas Irvin

R Bruce Lennox

Rosa P Yanmaele

Robert Murray Ratcliffe

Craig Railton

This invention relates to prevention and/or treatment of antibiotic associated diarrhea, including associated diarrhea (CDAD), pseudomembranous colitis (PMC) and other conditions associated with infection, using oligosaccharide compositions which bind toxin B. More specifically, the invention concerns neutralization of toxin B associated with such conditions.

Treatment of C. difficile toxin B associated conditions

Compounds which bind to toxins associated with enteric bacterial infection, compositions including the compounds, methods for the neutralization of toxins in a patient, and methods for the diagnosis of bacterial and viral infections are disclosed. Toxins which can be bound by the compounds include pentameric toxins, for example SLTs, such as those from salmonella, camylobacter and other bacteria, verotoxins from,, cholera toxin, clostridium difficile toxins A and B, bacterial pili from enteropathogenic,(EPEC) and enterotoxigenic,(ETEC) and viral lectins such as viral hemagglutinins. The compounds include a core molecule bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to at least one, and preferably, two or more ligands which bind to the toxin. The presence of a plurality of bridged dimers of the ligands is responsible for the increased binding affinity of the compounds relative to the ligands themselves. In one embodiment, the compounds, when administered in a timely fashion to a patient suffering from enteric,infection, inhibit progression of this infection into hemolytic uremic syndrome (HUS).

Treatment of bacterial infections

This invention relates to compositions and methods useful to treat diarrhea, especially diarrhea and related conditions initiated or mediated by enteropathogenic,(EPEC), using oligosaccharide compositions. This invention also relates to compositions and methods to reduce the virulence of an EPEC organism.

Treatment of diarrhea caused by enteropathogenic Escherichia coli

Therapeutic and diagnostic methods are provided for treatment and detection of enteropathogenic,(EPEC) enteric infections. Also provided is an assay for the identification of compositions which are effective inhibitors of EPEC infection.

Pharmaceutical compositions for the amelioration of enteropathogenic E. coli infection

The present invention is directed to lectin derived carbohydrate binding peptides or derivatives thereof useful for suppressing inflammatory responses, inducing tolerance to an antigen, and suppressing cell adhesion, e.g., involved in metastasis. In particular, peptides capable of binding terminally linked &agr;-sialic acid(2-6)&bgr;Gal- and/or &agr;-sialic acid(2-3)&bgr;Gal-groups on structures or molecules comprising such groups are provided. Pharmaceutical compositions containing such lectin derived carbohydrate binding peptides are also disclosed.

Anti-flammatory carbohydrate binding-peptides

This invention relates to the treatment of diarrhea and related conditions caused by pathogenic,infection. More specifically, this invention is drawn to the unexpected discovery that by administering a composition which binds and removes the shiga like toxins (SLT) produced by pathogenic,whenever an antibiotic is administered, improved treatment is provided. Novel compositions containing both antibiotic and toxin binding composition and methods of treatment which use simultaneous administration toxin binding composition whenever antibiotic is administered are provided. These compositions and methods kill the enteric,organisms which produce the conditions and neutralize the SLT produced by the organisms and/or released from the organisms when they are killed. Thus, these compositions and methods are better able to ameliorate the symptoms of the infection and inhibit progression of this infection into hemolytic uremic syndrome (HUS) than conventional treatment.

Compounds and methods for the treatment of bacterial dysentery using antibiotics and toxin binding oligosaccharide compositions

The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. These three-dimensional structures were analyzed to identify functional amino acids appropriate for modification to alter the biological properties of PT. Similar procedures may be used to predict amino acids which contribute to the toxicity of the holotoxin, to produce immunoprotective, genetically-detoxified analogs of pertussis toxin.

Modification of pertussis toxin

Disclosed are methods for the neutralization of shiga-like toxins (SLT) associated with enteric E. coli infection which methods inhibit progression of this infection into hemolytic uremic syndrome (HUS).

Treatment of bacterial dysentery

This invention relates to prevention and/or treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD), pseudomembranous colitis (PMC) and other conditions associated with C. difficile infection, using oligosaccharide compositions which bind C. difficile toxin B. More specifically, the invention concerns neutralization of C. difficile toxin B associated with such conditions.

Treatment of traveller's diarrhea

Growing community of inventors

Edmonton, Canada

Glen D Armstrong